<a href="https://www.fiercebiotech.com/biotech/ma-used-be-only-way-go-why-seaports-ceo-opted-upsized-255m-ipo" hreflang="en">‘M&A used to be the only way to go’: Why Seaport’s CEO opted for route to upsized $255M IPO</a>
Seaport Therapeutics successfully raised approximately $255 million through an upsized IPO, surpassing initial expectations, as it aims to independently develop its depression drug pipeline. Alongside, Hemab Therapeutics also exceeded its IPO target, raising over $300 million to fund its bleeding disorder treatments, indicating a strong resurgence in biotech IPOs.
The significant takeaway for someone tracking biotech IPOs is the successful upsized IPOs of Seaport Therapeutics and Hemab Therapeutics, which surpassed their initial targets, indicating a robust market interest in biotech IPOs. Specifically, Seaport's decision to pursue an IPO instead of an M&A reflects a growing trend where biotechs are opting to independently advance their drug pipelines to the market, leveraging platforms like Seaport's Glyph for enhanced drug delivery, potentially providing new investment opportunities in innovative drug development technologies.